Financial-condition grades for SEC filers
Company Report · as of Oct 9, 2026
|
| GT Biopharma, Inc.GTBP · healthcare | |
|---|---|
| Grade | Nonecomputable_factors_below_threshold: 2 of 14 inputs computable; 7 are required |
| Reliability | 0.76 AUCfailure model, filers with under $12.5M assets; 95% interval 0.65 to 0.86; 63 events, 2020 to 2025 |
| Peer failure rate | 0.60% a yearItem 1.03 bankruptcies, same asset band, 2012 to 2025 |
| Size band | under $12.5M assetstotal assets $8.1M[1] |
| Standard universe | outsiderevenue above $1M and assets above $10M[1-2] |
| Warnings | dilution, short runway, thin data, degenerate inputsnot computable: distress, fortress balance sheet |
| Inputs computable | 2 of 14 |
| Graded from | filings received through Mar 2, 2026221 days before the rescan; every figure keyed to the SEC receipt date |
| Last close | $6.222026-10-05; market equity $280.8M; iex feed |
| Price used in grade | None |
| Share price, twelve months to the rescansplit-adjusted close; a lollipop at every rescan carries the letter held then; baseline ticks are SEC receipt dates of the inputs; ranges and dragging scroll the full history | ||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Percentile at every rescan on file, Jan 21, 2012 to Oct 9, 2026; stronger toward the top. Hover for the date. Open this report as it stood on | ||||||||||||||||||||||||||||||||
Each date opens the report as it stood on that rescan. |
Business, in the company's words. Opening of Item 1 of the 10-K received Mar 2, 2026; the document on sec.gov.
are a clinical stage biopharmaceutical company focused on the development and commercialization of novel immuno-oncology products based on our proprietary Tri-specific Killer Engager (“TriKE®”), and Tetra-specific Killer Engager (“Dual Targeting TriKE®”) fusion protein immune cell engager technology platforms. Our TriKE® and Dual Targeting TriKE® platforms generate proprietary therapeutics designed to harness and enhance the cancer killing abilities of a patient’s own natural killer cells (“NK cells”).
7 checks ran; none of them enters the letter. The checks are listed on the warnings screen.
Lower percentile is stronger. Source numbers open the SEC filing; a range that spans filings opens the sources table.
| Input | Percentile, 0 to 100 | Value | Source | Peer median | Percentile | Peers | Period end |
|---|---|---|---|---|---|---|---|
| Profitability | |||||||
| Gross profitability | not computable | 32.2% | |||||
| latest aligned inputs end 2017-12-31; latest annual assets end 2025-12-31 | |||||||
| Return on invested capital | not computable | 9.3% | |||||
| one or more required annual facts are missing | |||||||
| Accruals ratio | not computable | (6.6%) | |||||
| prior assets observation is 92 days earlier | |||||||
| Gross margin stability, five years | not computable | 2.8 pts | |||||
| annual revenue must exceed $100,000 | |||||||
| Solvency, sleeve percentile 52.0 | |||||||
| Twelve-month failure probability | not computable | 0.07% | |||||
| liabilities and a nearby cover-page share count are required at 2026-06-30 | |||||||
| Altman Z double-prime | not computable | (0.31) | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Net debt to EBITDA | not computable | 1.82x | |||||
| one or more required annual facts are missing | |||||||
| Interest coverage | not computable | (4.51x) | |||||
| latest aligned inputs end 2023-12-31; latest annual assets end 2025-12-31 | |||||||
| Current ratio | 3.50x | [6-7] | 2.96x | 52.0 | 839 | 2025-12-31 | |
| Growth and financing, sleeve percentile 97.0 | |||||||
| Revenue growth, three-year compound | not computable | 10.0% | |||||
| four consecutive annual observations are required | |||||||
| Free cash flow growth, three-year compound | not computable | 10.9% | |||||
| current FCF must be positive and base FCF must exceed $100,000 | |||||||
| Reinvestment rate | not computable | 37.1% | |||||
| latest aligned inputs end 2019-12-31; latest annual assets end 2025-12-31 | |||||||
| Asset growth, three years | not computable | 2.1% | |||||
| four consecutive annual observations are required | |||||||
| Net share issuance, one year | 1,312.2% | [3-4] | 2.5% | 97.0 | 634 | 2026-02-23 | |
Gross profitability. Revenue less cost of goods sold, over total assets.
Accruals ratio. Net income less operating cash flow, over average assets; lower is stronger.
Gross margin stability, five years. Standard deviation of gross margin; lower is stronger.
Twelve-month failure probability. CHS model; lower is stronger.
Net debt to EBITDA. Lower is stronger.
Net share issuance, one year. Split-adjusted; lower is stronger.
Market measures at the 2026-10-05 close. None enters the grade. Percentile among graded peers with the same measure.
| Measure | Value | Peer median | Percentile | Reading |
|---|---|---|---|---|
| Twelve-month price change, skipping the latest month | 1,119.1% | 8.0% | 100 | hotter than 100 of 100 peers |
| Distance from 52-week high | (48.8%) | (31.4%) | 29 | closer to its high than 29 of 100 peers |
| EBIT to enterprise value | not computable | (1.5%) | required accounting or market input is missing | |
| Free cash flow yield | (1.4%) | (1.0%) | 48 | pricier than 52 of 100 peers |
| Book value to price | 0.01 | 0.28 | 14 | pricier than 86 of 100 peers |
| Sales to price | 0.00 | 0.31 | 0 | pricier than 100 of 100 peers |
| Composite equity issuance, five years | 386.4% | 20.3% | 97 | more equity-funded than 97 of 100 peers |
| Relative strength against the sector, log excess return | 2.29 | (0.14) | 100 | ahead of 100 of 100 peers |
Inputs: market equity $268.9M; EBIT -$12.4M; free cash flow -$3.7M; book equity $3.6M; sales $0; cash $5.0M[8].
Diagnostics do not feed the grade.
| Piotroski F-score: None of 9, period end 2025-12-31 | ||
|---|---|---|
| Return on assets above zero | n/a | |
| Operating cash flow above zero | -$12.9M | ✗ fail[9] |
| Return on assets improved | n/a[10] | |
| Operating cash flow exceeds net income | $15.4M | ✓ pass[9-10] |
| Long-term leverage fell | n/a[1] | |
| Current ratio improved | n/a[6-7] | |
| No new shares issued | 1,312.2% | ✗ fail[3-4] |
| Gross margin improved | n/a | |
| Asset turnover improved | n/a | |
| Cash, filings, liquidity | |
|---|---|
| Cash and equivalents | $5.0M[5] |
| Operating cash flow, four quarters | -$14.4M[5,9,11-14] |
| Months of runway | 4.1 |
| Late filings, two years | 0 |
| NT 10-K or NT 10-Q | |
| Days since last periodic filing | 56 |
| 10-Q received Aug 14, 2026 | |
| Median daily dollar volume | $177,206 |
| 63 sessions | |
| Days since newest grade input | 221 |
|
Every citation on this page. Filing opens the SEC index page for that submission; viewer opens the SEC interactive data for the same filing; series opens the SEC XBRL API record for that tag and company.
| # | Concept | XBRL tag | Value | Period end | Received | Form | Links |
|---|---|---|---|---|---|---|---|
| 1 | assets | us-gaap:Assets | $8.1M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 2 | revenue | us-gaap:Revenues | $0 | 2020-12-31 | 2021-04-16 | 10-K | filing · viewer · series |
| 3 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 31,553,892 | 2026-02-23 | 2026-03-02 | 10-K | filing · viewer · series |
| 4 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 2,234,328 | 2025-02-19 | 2025-04-14 | 10-K/A | filing · viewer · series |
| 5 | cash | us-gaap:CashAndCashEquivalentsAtCarryingValue | $5.0M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 6 | current assets | us-gaap:AssetsCurrent | $8.1M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 7 | current liabilities | us-gaap:LiabilitiesCurrent | $2.3M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 8 | shares outstanding | dei:EntityCommonStockSharesOutstanding | 45,109,497 | 2026-08-10 | 2026-08-14 | 10-Q | filing · viewer · series |
| 9 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$12.9M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 10 | net income | us-gaap:NetIncomeLoss | -$28.4M | 2025-12-31 | 2026-03-02 | 10-K | filing · viewer · series |
| 11 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$6.7M | 2026-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
| 12 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$2.5M | 2026-03-31 | 2026-05-15 | 10-Q | filing · viewer · series |
| 13 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$8.9M | 2025-09-30 | 2026-03-06 | 10-Q/A | filing · viewer · series |
| 14 | operating cash flow | us-gaap:NetCashProvidedByUsedInOperatingActivities | -$5.2M | 2025-06-30 | 2026-08-14 | 10-Q | filing · viewer · series |
Peer group. Sector assignment from four-digit SIC codes, hand-tuned and published. The grade under three alternative peer policies is tabled above.
Size. Within a sector the letter tracks size. Among graded filers in the smallest asset band, 72% grade E and 0% grade A; in the largest, 13% grade E and 21% grade A. Universe as of Oct 9, 2026.
Failure model. filings 2012-01-01 to 2019-12-31 fit, filings 2020-01-01 to 2025-12-31 test; status post hoc pending confirmation. pre-registered on 2026 filings once their 12-month outcome windows close; supported if the paired per-quintile gain over the pooled model has a lower bound above 0.05.
Input validity. Revenue or total assets at or below $100,000 sets the degenerate-inputs flag. An input whose denominator is at or below $100,000 is left not computable rather than ranked.
Returns. No input on this page has a post-2015 confidence interval on returns that excludes zero. The grade ranks reported financial condition and is not a return forecast.